Nothing Special   »   [go: up one dir, main page]

HK1058314A1 - Method for preparing a composition - Google Patents

Method for preparing a composition

Info

Publication number
HK1058314A1
HK1058314A1 HK04101186A HK04101186A HK1058314A1 HK 1058314 A1 HK1058314 A1 HK 1058314A1 HK 04101186 A HK04101186 A HK 04101186A HK 04101186 A HK04101186 A HK 04101186A HK 1058314 A1 HK1058314 A1 HK 1058314A1
Authority
HK
Hong Kong
Prior art keywords
preparing
solution
homogeneous dispersion
compositions
composition
Prior art date
Application number
HK04101186A
Other languages
English (en)
Inventor
Patrick Busson
Marco Schroeder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1058314(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1058314A1 publication Critical patent/HK1058314A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK04101186A 2000-06-27 2004-02-19 Method for preparing a composition HK1058314A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00113535 2000-06-27
PCT/EP2001/006834 WO2002000201A2 (en) 2000-06-27 2001-06-18 Method for preparing a composition

Publications (1)

Publication Number Publication Date
HK1058314A1 true HK1058314A1 (en) 2004-05-14

Family

ID=8169074

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04101186A HK1058314A1 (en) 2000-06-27 2004-02-19 Method for preparing a composition

Country Status (38)

Country Link
US (3) US6534087B2 (es)
EP (1) EP1296656B1 (es)
JP (2) JP4149803B2 (es)
KR (1) KR100557845B1 (es)
CN (1) CN1236764C (es)
AR (1) AR029278A1 (es)
AT (1) ATE334662T1 (es)
AU (2) AU2001281846B2 (es)
BR (1) BRPI0112014B1 (es)
CA (1) CA2411153C (es)
CY (1) CY1105714T1 (es)
CZ (1) CZ301813B6 (es)
DE (1) DE60121953T2 (es)
DK (1) DK1296656T3 (es)
EC (1) ECSP024401A (es)
EG (1) EG24141A (es)
ES (1) ES2269441T3 (es)
HK (1) HK1058314A1 (es)
HR (1) HRP20021009B1 (es)
HU (1) HU229550B1 (es)
IL (2) IL153282A0 (es)
JO (1) JO2247B1 (es)
MA (1) MA26922A1 (es)
ME (1) MEP90608A (es)
MX (1) MXPA02012583A (es)
MY (1) MY129798A (es)
NO (1) NO332181B1 (es)
NZ (1) NZ523024A (es)
PE (1) PE20020101A1 (es)
PL (1) PL203804B1 (es)
PT (1) PT1296656E (es)
RU (1) RU2244542C2 (es)
SI (1) SI1296656T1 (es)
TW (1) TWI278325B (es)
UY (1) UY26799A1 (es)
WO (1) WO2002000201A2 (es)
YU (1) YU96602A (es)
ZA (1) ZA200209649B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
AU2001281846B2 (en) * 2000-06-27 2006-04-27 Cheplapharm Arzneimittel Gmbh Method for preparing a composition
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
MY135783A (en) * 2001-09-07 2008-06-30 Meiji Dairies Corp Nutritional composition for controlling blood sugar level
ATE453390T1 (de) 2002-04-26 2010-01-15 Hoffmann La Roche Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
KR100517072B1 (ko) * 2002-11-25 2005-09-26 주식회사 태평양 폴리올/고분자 마이크로캡슐 및 이를 이용한 효소 안정화방법
US9174176B2 (en) 2003-01-09 2015-11-03 Disperse Systems, Inc. Ultrasonic dispersion apparatus, system, and method
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
ES2552936T3 (es) 2003-12-12 2015-12-03 Otic Pharma Ltd. Composiciones para el tratamiento del desordenes en el oído y métodos para el uso de los mismos
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
AU2005244329A1 (en) * 2004-04-06 2005-11-24 Rpg Life Sciences Limited Mouth dissolvable and meltable, and water dispersable delivery formulation
WO2006030784A1 (ja) * 2004-09-15 2006-03-23 Banyu Pharmaceutical Co., Ltd. サンプリング方法、サンプリング装置、ｌｏｇＤ測定方法及びｌｏｇＤ測定システム
US20100015057A1 (en) * 2004-12-31 2010-01-21 Mikhail Yurievich Gotovskiy Magnetoresonance preparations, device for individually selecting said preparations for increasing an organism life activity in actual environmental conditions
US20060198856A1 (en) * 2005-03-01 2006-09-07 Keith Whitehead Ibuprofen suspension stabilized with docusate sodium
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US7984717B2 (en) * 2005-04-29 2011-07-26 Medtronic, Inc. Devices for augmentation of lumen walls
WO2006138431A2 (en) * 2005-06-16 2006-12-28 Eastman Chemical Company Methods and pharmaceutical formulations for increasing bioavailability
WO2006136197A1 (en) 2005-06-21 2006-12-28 V. Mane Fils Smoking device incorporating a breakable capsule, breakable capsule and process for manufacturing said capsule
US20070048364A1 (en) * 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8097245B2 (en) 2005-12-28 2012-01-17 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
FR2895908B1 (fr) * 2006-01-12 2008-03-28 France Etat Procede de fabrication d'une forme pharmaceutique de phosphate d'oseltamivir
US9012499B2 (en) 2006-02-20 2015-04-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
WO2007109127A2 (en) 2006-03-16 2007-09-27 Duke University Methods, systems, and computer program products for performng real-time quadrature projection based fourier domain optical coherence tomography
CN1820744B (zh) 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
KR100812824B1 (ko) 2006-09-27 2008-03-12 주식회사 제닉 키토산과 폴리에틸렌글리콜을 이용한 생체친화성 저독성필름
WO2008076975A1 (en) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation A dry food product containing live probiotic
NZ582049A (en) * 2007-05-18 2012-12-21 Tti Ellebeau Inc Transdermal delivery devices assuring an improved release of an active principle through a biological interface
KR101439470B1 (ko) * 2007-05-22 2014-09-16 한미사이언스 주식회사 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
GB0900551D0 (en) * 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
CA2986751A1 (en) 2009-03-27 2010-09-30 Intervet International B.V. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
DK2435554T3 (en) 2009-05-26 2017-10-30 Advanced Bionutrition Corp STABLE DRY POWDER COMPOSITION WITH BIOLOGICALLY ACTIVE MICRO-ORGANISMS AND / OR BIOACTIVE MATERIALS AND PROCEDURES FOR ITS PREPARATION
EP2482802A4 (en) * 2009-09-29 2013-08-07 Michael Burnet NEW PESTICIDE FORMULATIONS
KR100940745B1 (ko) * 2009-10-15 2010-02-04 광동제약 주식회사 오를리스타트 및 아타풀지트 함유 복합제의 코팅펠렛 및 이를 이용한 제제
ES2639397T3 (es) 2010-01-28 2017-10-26 Advanced Bionutrition Corporation Composición vítrea seca que comprende un material bioactivo
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
KR101021030B1 (ko) * 2010-03-25 2011-03-09 엘지이노텍 주식회사 형광체 코팅방법, 발광장치 제조방법 및 코팅된 형광체
NO2557151T3 (es) * 2010-04-07 2018-03-03
RS57588B1 (sr) 2010-08-13 2018-11-30 Advanced Bionutrition Corp Supstanca za stabilizaciju bioloških materijala za suvo skladištenje
US9492387B2 (en) * 2010-10-29 2016-11-15 Western University Of Health Sciences Ternary mixture formulations
US9005635B2 (en) 2011-03-01 2015-04-14 The Procter & Gamble Company Articles and processes for making a porous disintegratable solid substrate for personal health care applications
BR112014023234B1 (pt) 2012-03-23 2020-12-08 Advanced Bionutrition Corporation composição de estabilização seca em um estado vítreo amorfo para um material bioativo, método para produzir a referida composição e produtos preparados com a mesma
CN103222964B (zh) * 2013-01-29 2014-10-08 青岛大学 一种奥利司他口服制剂及其制备方法
GB2524496A (en) * 2014-03-24 2015-09-30 British Airways Plc Dynamic tracking and control of passenger travel progress
MX2017016924A (es) 2015-06-25 2018-08-15 Ascus Biosciences Inc Métodos, aparatos y sistemas para analizar cepas de microorganismos de comunidades heterogéneas complejas, predecir e indentificar sus relaciones funcionales e interacciones y seleccionar y sintetizar conjuntos microbianos basados en estos.
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
DK3328215T3 (da) 2015-07-29 2021-09-13 Advanced Bionutrition Corp Stabilt tørre probiotiske sammensætninger til særlige kostanvendelser
JP6778051B2 (ja) * 2016-08-18 2020-10-28 沢井製薬株式会社 オセルタミビルリン酸塩含有医薬組成物
AU2017386658A1 (en) 2016-12-28 2019-07-25 Native Microbials, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
AU2017388535A1 (en) 2016-12-28 2019-07-25 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles including dosed microbial ensembles and inoculative microbial ensembles
WO2019069108A1 (en) * 2017-10-04 2019-04-11 Debreceni Egyetem SOLID GALENIC FORM, MOLDED, GASTRIC RETENTION AND EXTENDED RELEASE AND METHOD OF PREPARING THE SAME

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
US4489438A (en) * 1982-02-01 1984-12-18 National Data Corporation Audio response system
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
ATE216577T1 (de) 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd Schnellösliche tablette und ihre herstellung
US5560921A (en) 1992-06-01 1996-10-01 The Procter & Gamble Company Chewable decongestant compositions
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
CA2151260A1 (en) * 1993-02-23 1994-09-01 Pankaj B. Gala A process for the preparation of substantially alcohol free pharmaceutical compositions
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5536264A (en) * 1993-10-22 1996-07-16 The Procter & Gamble Company Absorbent composites comprising a porous macrostructure of absorbent gelling particles and a substrate
US5523106A (en) * 1994-02-03 1996-06-04 Nabisco, Inc. Juice-based expanded snacks and process for preparing them
US5952375A (en) 1995-02-27 1999-09-14 Gilead Sciences, Inc. Compounds and methods for synthesis and therapy
CA2188835C (en) 1995-02-27 2006-08-08 Norbert W. Bischofberger Novel compounds and methods for synthesis and therapy
EP0831790B1 (en) * 1995-06-07 2003-05-07 Elan Drug Delivery Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
US5763483A (en) * 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
DK0893992T3 (da) * 1996-04-16 2004-06-01 Novartis Consumer Health Sa Hurtigt sönderdelende oral doseringsform
US5766520A (en) * 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
CN1233169A (zh) * 1996-10-14 1999-10-27 弗·哈夫曼-拉罗切有限公司 一种粉末状制剂的制备工艺
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
JPH11137208A (ja) 1997-11-14 1999-05-25 Nikken Chem Co Ltd 口腔内速溶性固形物及びその製造方法
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
ES2272066T3 (es) * 1998-04-09 2007-04-16 F. Hoffmann-La Roche Ag Proceso para la manufactura de particulas con tamaño de (sub)micras por disolucion de gas comprimido y surfactantes.
CA2340052C (en) 1998-08-14 2007-05-29 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
ES2242413T3 (es) 1998-08-14 2005-11-01 F. Hoffmann-La Roche Ag Composiciones farmaceuticas que contienen inhibidores de lipasa.
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
GB9904629D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Oral drug delivery system
FR2791569B1 (fr) * 1999-03-31 2003-05-09 Pf Medicament Composition ou structure microporeuse expansee isotrope a dissolution rapide a usage pharmaceutique, veterinaire, dietetique, alimentaire ou cosmetique et son procede d'obtention
AU2001281846B2 (en) * 2000-06-27 2006-04-27 Cheplapharm Arzneimittel Gmbh Method for preparing a composition

Also Published As

Publication number Publication date
KR100557845B1 (ko) 2006-03-10
MA26922A1 (fr) 2004-12-20
CY1105714T1 (el) 2010-12-22
US6534087B2 (en) 2003-03-18
PL365803A1 (en) 2005-01-10
BR0112014A (pt) 2003-05-13
RU2244542C2 (ru) 2005-01-20
UY26799A1 (es) 2001-12-28
NZ523024A (en) 2004-08-27
ATE334662T1 (de) 2006-08-15
CN1236764C (zh) 2006-01-18
WO2002000201A2 (en) 2002-01-03
PE20020101A1 (es) 2002-02-12
ECSP024401A (es) 2003-02-06
CZ2003212A3 (cs) 2003-06-18
BRPI0112014B1 (pt) 2016-09-13
DK1296656T3 (da) 2006-11-27
MXPA02012583A (es) 2003-04-10
DE60121953D1 (de) 2006-09-14
JP2007302683A (ja) 2007-11-22
SI1296656T1 (sl) 2006-12-31
CA2411153C (en) 2007-01-30
EP1296656B1 (en) 2006-08-02
ES2269441T3 (es) 2007-04-01
DE60121953T2 (de) 2007-03-08
IL153282A0 (en) 2003-07-06
HUP0302060A2 (hu) 2003-09-29
CZ301813B6 (cs) 2010-06-30
JO2247B1 (en) 2004-10-07
ZA200209649B (en) 2004-03-10
HUP0302060A3 (en) 2006-07-28
NO332181B1 (no) 2012-07-16
KR20030023880A (ko) 2003-03-20
EP1296656A2 (en) 2003-04-02
ME00672B (me) 2011-12-20
AU8184601A (en) 2002-01-08
HRP20021009B1 (en) 2011-07-31
AR029278A1 (es) 2003-06-18
US20020018812A1 (en) 2002-02-14
MEP90608A (en) 2011-12-20
MY129798A (en) 2007-04-30
HU229550B1 (en) 2014-01-28
YU96602A (sh) 2005-03-15
JP4149803B2 (ja) 2008-09-17
CN1438880A (zh) 2003-08-27
CA2411153A1 (en) 2002-01-03
IL153282A (en) 2008-03-20
PL203804B1 (pl) 2009-11-30
NO20026197D0 (no) 2002-12-23
EG24141A (en) 2008-08-06
NO20026197L (no) 2002-12-23
HRP20021009A2 (en) 2004-02-29
JP2004501184A (ja) 2004-01-15
US20060134205A1 (en) 2006-06-22
PT1296656E (pt) 2006-12-29
TWI278325B (en) 2007-04-11
WO2002000201A3 (en) 2002-04-18
AU2001281846B2 (en) 2006-04-27
US20030039614A1 (en) 2003-02-27
US7074431B2 (en) 2006-07-11

Similar Documents

Publication Publication Date Title
JO2247B1 (en) Method for preparing a compound
WO2001089479A3 (en) Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
ZA200301813B (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
WO2003002136A3 (en) Stable formulation of modified glp-1
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
EP1040823A3 (en) Stable foam compositions
WO2005009356A3 (en) Method for the preparation of controlled release formulations
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
WO2002015959A3 (en) Compounds and compositions for delivering active agents
HUP0301075A3 (en) Diphenyl ether derivatives, their use for preparation of pharmaceutical compositions and process for preparation the compounds
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
IL161983A0 (en) Preparation compositions containing acid-unstable physiologically active compounds, and process for producing the same
MXPA02009705A (es) Nueva combinacion de un betabloqueador y un agente de disminucion de colesterol.
YU72802A (sh) Farmaceutske smeše koje sadrže oligosaharide, novi oligosaharidi i njihovo dobijanje
EP1245562A4 (en) ALCOHOLS 5-THIA- "OMEGA" - (PHENYL SUBSTITUTED) - PROSTAGLANDIN E, PROCESS FOR THE PREPARATION OF SUCH ALCOHOLS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE ALCOHOLS AS ACTIVE INGREDIENT.
WO2002006299A3 (en) Therapeutic uses for aminosterol compounds
WO2002041875A3 (de) Verfahren zur herstellung leicht löslicher arzneimittelformulierungen und entsprechende formulierungen
WO2001097751A3 (en) New formulation comprising a betablocker and optionally a cholesterol-lowering agent
CA2195079A1 (en) Aqueous foamable composition
CA2066945A1 (en) Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20210617